Veterinary Medicines Directorate

**United Kingdom**
**Veterinary Medicines Directorate**
**Woodham Lane**
**New Haw**
**Addlestone**
**Surrey KT15 3LS**

**NATIONAL PROCEDURE**

# PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

**Soliphen 15 mg Tablet for Dogs**
**Soliphen 120 mg Tablet for Dogs**

**Date Created: May 2022**

# MODULE 1

## PRODUCT SUMMARY

| | |
|---|---|
| Name, strength and pharmaceutical form | Soliphen 15 mg Tablet for Dogs<br>Soliphen 120 mg Tablet for Dogs |
| Applicant | Domes Pharma<br>3 Rue Andre Citroën<br>Pont-Du-Chateau<br>63430<br>France |
| Active substance | Phenobarbital |
| ATC Vetcode | QN03AA02 |
| Target species | Dogs |
| Indication for use | Prevention of seizures due to generalised epilepsy in dogs. |

# MODULE 2

The Summary of Product Characteristics (SPC) for this product is available on the Product Information Database of the Veterinary Medicines Directorate.

(www.gov.uk/check-animal-medicine-licensed)

# MODULE 3

## PUBLIC ASSESSMENT REPORT

| | |
|---|---|
| Legal basis of original application | Generic hybrid application in accordance with Article 13(3) of Directive 2001/82/EC as amended. |
| Date of conclusion of the procedure | 23/3/2022 |

## I. SCIENTIFIC OVERVIEW

These are applications for extensions to an existing product to add two new tablet strengths.

This was determined a generic 'hybrid' application because changes to the strength with regard to the reference medicinal product have been made.

The product is produced and controlled using validated methods and tests which ensure the consistency of the product released on the market. It has been shown that the product can be safely used in the target species, any reactions observed are indicated in the SPC[1]. The product is safe for the user, and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC. The efficacy[2] of the product was demonstrated according to the claims made in the SPC. The overall benefit/risk analysis is in favour of granting a marketing authorisation.

## II. QUALITATIVE AND QUANTITATIVE PARTICULARS OF THE CONSTITUENTS

### *II.A. Composition*

The product contains phenobarbital and the excipients: microcrystalline cellulose, pregelatinized starch, lactose monohydrate, colloidal hydrated silica, pig liver flavour, dried yeast from *Saccharomyces* and magnesium stearate.

The container/closure system consists of PVC/aluminium thermosealed blisters. The particulars of the containers and controls performed are provided and conform to the regulation.

The choice of the formulation and the absence of preservative are justified.

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

[1] SPC – Summary of product Characteristics.
[2] Efficacy – The production of a desired or intended result.

## II.B. Description of the Manufacturing Method

The product is manufactured fully in accordance with the principles of good manufacturing practice from a licensed manufacturing site. The manufacturing process is standard and allow an appropriate compressibility of phenobarbital and flavouring agents.
The manufacturing process is satisfactorily described, and relevant in-process controls are specified. Manufacturing process validation was carried out on pilot-scale batches for the 15 mg tablets and the 120 mg tablets.

## II.C. Control of Starting Materials

The active substance is phenobarbital, an established active substance described in the European Pharmacopoeia. The active substance is manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

The active substance is sourced with a current CEP.

All excipients are described in Ph. Eur. except for pig liver flavour and dried yeast from *Saccharomyces* which are described in in-house monographs.

The packaging is described in the CEP.

### II.C.4. Substances of Biological Origin

Scientific data and/or certificates of suitability issued by the EDQM have been provided and compliance with the Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Human and Veterinary Medicinal Products has been satisfactorily demonstrated.

## II.D. Control Tests Carried Out at Intermediate Stages of the Manufacturing Process

Not applicable.

## II.E. Control Tests on the Finished Product

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product. Satisfactory validation data for the analytical methods have been provided. Batch analytical data from the proposed production site have been provided demonstrating compliance with the specification. Control tests on the finished product are those for: appearance, phenobarbital identification, average

mass, uniformity, disintegration, dissolution, residual moisture, friability, resistance to crushing, subdivision of tablets, phenobarbital content, phenobarbital degradation products, and microbiological controls.

### *II.F. Stability*

Stability data on the active substance have been provided in accordance with applicable European guidelines in the original application, demonstrating the stability of the active substance when stored under the approved conditions.

### *G. Other Information*

Soliphen 15 mg:
Shelf life of the veterinary medicinal product as packaged for sale: 30 months.
Store below 30°C. Keep the tablets in the original package. Any remaining portions of divided tablets should be replaced in the blister pocket, the blister strip should be returned to the cardboard box.

Soliphen 120 mg:
Shelf life of the veterinary medicinal product as packaged for sale: 3 years.
Keep the tablets in the original package. Any remaining portions of divided tablets should be replaced in the blister pocket, the blister strip should be returned to the cardboard box.

## III. SAFETY AND RESIDUES DOCUMENTATION (PHARMACO-TOXICOLOGICAL)

### *III.A Safety Documentation*

As this is an extension application for additional strengths of tablet (15 mg and 120 mg), including a higher strength, the applicant has not provided toxicological and pharmacological data on the active substances or formulation

### *User Safety*

A user risk assessment was provided in compliance with the relevant guideline.

Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product. Therefore the following applicant's user recommendations are appropriate:

- Barbiturates can cause hypersensitivity. People with known hypersensitivity to barbiturates should avoid contact with the veterinary medicinal product.
- Accidental ingestion may cause intoxication and could be fatal, particularly for children. Take utmost care that children do not come in contact with the veterinary medicinal product. Keep this product in its original packaging to avoid accidental ingestion. Each time an unused

part-tablet is stored until next use, it should be returned to the open blister space and inserted back into the cardboard box.
- Phenobarbital is teratogenic and may be toxic to unborn and breastfeeding children; it may affect the developing brain and lead to cognitive disorders. Phenobarbital is excreted in breast milk. Pregnant women, women of childbearing age and lactating women should avoid accidental ingestion and prolonged skin contact with the product.
- It is advisable to wear disposable gloves during administration of the product to reduce skin contact.
- In case of accidental ingestion, seek medical attention immediately, advising medical services of barbiturate poisoning; show the package leaflet or the label to the physician. If possible, the physician should be informed about the time and amount of ingestion, as this information may help to ensure that appropriate treatment is given.
- Wash hands thoroughly after use.

### *Environmental Safety*

The Environmental Risk Assessment (ERA) was carried out in accordance with VICH and CVMP guidelines.

**Phase I:**

The product will only be used in non-food animals and as a result environmental exposure will be low. A Phase II ERA was not required.

## IV. CLINICAL DOCUMENTATION

### *IV.I. Pre-Clinical Studies*

### *Pharmacology*

In the generic application, identical composition, quality of ingredients and manufacturing between the generic and the reference product have been demonstrated, and the dissolution profiles for Soliphen 15 and 120 mg and the reference product are considered similar, the applicant is therefore not required to provide additional information on pharmacology or pharmacodynamics.

### *Tolerance in the Target Species*

Tolerance studies were not required because the tolerance is not expected to be different from the authorised strength.

### *IV.II. Clinical Documentation*

The conditions for granting a biowaiver have been fulfilled, no further clinical data are provided and reference to the reference product dossier can be made.

# V OVERALL CONCLUSION AND BENEFIT– RISK ASSESSMENT

The data submitted in the dossier demonstrate that the benefit/risk profiles of the products are favourable.

# MODULE 4

## POST- AUTHORISATION ASSESSMENTS

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the Product Information Database of the Veterinary Medicines Directorate website.

(www.gov.uk/check-animal-medicine-licensed)

The post-authorisation assessment (PAA) contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

The PAA for this product is available on the Product Information Database of the Veterinary Medicines Directorate website.

(www.gov.uk/check-animal-medicine-licensed)